Study Name:
A Study of MK-1084 Plus Pembrolizumab in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer With Programmed Cell Death Ligand 1 Tumor Proportion Score ≥50%
Targeted Disease(s):
Lung Cancer
Purpose of Study:
This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%.
Study Dates:
May 24, 2024 - February 18, 2031
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Funding Source:
Merck Sharp & Dohme LLC
Contact:
1-888-577-8839
[email protected]
ClinicalTrails.gov Identifier:
NCT06345729
